Jacob Chacko - Jun 26, 2023 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Stock symbol
ORIC
Transactions as of
Jun 26, 2023
Transactions value $
-$160,562
Form type
4
Date filed
6/28/2023, 07:18 PM
Previous filing
May 25, 2023
Next filing
Jul 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Sale -$161K -20K -2.44% $8.03 801K Jun 26, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $8.00 to $8.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Includes 4,000 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.